Articles by admin

No Image

Facebook Could Face Up To $5 Billion Fine For Privacy Violations

Facebook CEO Mark Zuckerberg speaks during the Facebook F8 developers conference on May 1, 2018, in San Jose, Calif.

Justin Sullivan/Getty Images


hide caption

toggle caption

Justin Sullivan/Getty Images

Facebook expects to pay a fine of up to $5 billion in a settlement with federal regulators. The tech giant disclosed that figure in its first-quarter 2019 financial results.

Facebook has been in negotiations with the Federal Trade Commission following concerns that the company violated a 2011 consent decree. Back then, company leaders promised to give consumers “clear and prominent notice” when sharing their data with others and to get “express consent.”

But, experts say, Facebook broke its promise. Just one example: giving user data to Cambridge Analytica, the political consulting firm that did work for the 2016 Trump campaign.

Facebook estimates the fine will be in the $3 billion to $5 billion range and has set aside $3 billion for payment. The company’s statement says, “The matter remains unresolved, and there can be no assurance as to the timing or the terms of any final outcome.”

This would not be the largest fine issued by the FTC. In 2016, the agency reached settlements with Volkswagen totaling up to $14.7 billion. Facebook’s total revenue for the first quarter stood at more than $15 billion. So whatever the final figure, the company has the money to pay for the estimated fine.

Facebook’s monthly active users stand at 2.38 billion, an increase of 8% year over year.

In an earnings call, CEO Mark Zuckerberg did not discuss the settlement in any detail. He focused his remarks on outlining Facebook’s plans for growth, which include building a private messaging platform. He also pointed to the European model of privacy regulation as one that could work globally, if other countries chose to follow suit.

Let’s block ads! (Why?)


No Image

Damian Lillard Leads Portland Trail Blazers To Victory In First Round Of NBA Playoffs

One player has excelled in the NBA playoffs: Damian Lillard. The all-star point guard has carried the Portland Trail Blazers all season thanks to his play and, more importantly, his leadership.



AUDIE CORNISH, HOST:

The National Basketball Association playoffs officially are on Lillard time. That’s the phrase all-star point guard Damian Lillard of the Portland Trail Blazers uses when he does something dramatic, which is often. But last night in Portland, Ore., Lillard went to new heights in leading his team to a first-round NBA playoff series victory over the Oklahoma City Thunder.

NPR’s Tom Goldman was there and has this report.

TOM GOLDMAN, BYLINE: This was going to be a story about Damian Lillard’s leadership, how he has carried a Trail Blazers team through a season of injuries and insults with a steady maturity that feels older than his 28 years. We’ll still get to that. But first we’ve got to talk about this.

(SOUNDBITE OF CHEERING)

GOLDMAN: Last night at Portland’s Moda Center with the score tied 115 all, the game clock a few ticks from zero, Lillard launched a jump shot from near the Blazers half-court logo. And, well, that roar wasn’t for a miss. The shot gave Lillard 50 points for the night, and it vanquished Oklahoma City, a team that owned Portland this regular season, winning all four games. Portland almost got even in the playoff series, winning four games to one. Portland head coach Terry Stotts got to the postgame interview room, sat down and smiled.

(SOUNDBITE OF ARCHIVED RECORDING)

TERRY STOTTS: The legend grows.

GOLDMAN: Lillard’s legend-building, buzzer-beating, series-winning shot was his second. He did it against the Houston Rockets in 2014. But last night was bigger. It came almost exactly a year after one of his most humiliating moments. New Orleans swept Portland out of the first round of the 2018 playoffs largely because it shut down Lillard. His reaction planted the seed for last night.

(SOUNDBITE OF ARCHIVED RECORDING)

DAMIAN LILLARD: I was like, I’m just going to accept responsibility that we didn’t play well. It was embarrassing. But when you go through stuff like that and you stay together and you keep working, you keep believing in what we do.

GOLDMAN: That attitude fueled a successful regular season run. But suddenly, late last month, that success seemed like it might come crashing to a halt.

(SOUNDBITE OF ARCHIVED RECORDING)

UNIDENTIFIED SPORTSCASTER: The left leg buckled, and Nurk is down, and he is in considerable pain, and he has a serious injury.

GOLDMAN: As heard on NBC Sports Northwest, Portland’s starting center, Jusuf Nurkic, suffered a compound fracture of his left leg. He’d been having the best season of his young career. Among those saddened for Nurkic and the Blazers was Randy Rahe, Lillard’s former college coach at Weber State. Rahe still stays in close contact with his former star.

RANDY RAHE: When Nurkic went down, you know, I texted him. I says, gosh, dang it, this is a tough one – tough one. And his text back was we’ll be fine, coach; we’ll be fine.

GOLDMAN: That’s the same message Lillard sent to his teammates. Basketball pundits insisted Portland wouldn’t be fine, saying the wounded Blazers were the team everyone wanted to play in the postseason. But since the Nurkic injury, Portland’s won 12 games, lost three. Rahe says Lillard’s season-long mission of building a culture of trust and togetherness shows.

RAHE: The connectedness of the team is really evident when you watch it right now.

GOLDMAN: Of course leadership sometimes means strapping a team to your back and making eye-popping, three-point winning shots, which Lillard did last night and more. During the Oklahoma City series, Lillard and his teammates stayed calm in the face of OKC’s trash-talking. But following the final shot, Lillard raised his right arm and waved at the OKC bench.

LILLARD: The series was over. You know, that was it. And I was just waving goodbye to them.

GOLDMAN: After a long year of pessimism and criticism, last night, Damian Lillard had the last word, maybe with more to come. Tom Goldman, NPR News, Portland.

(SOUNDBITE OF MY MORNING JACKET’S “I’M AMAZED”)

Copyright © 2019 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.

Let’s block ads! (Why?)


No Image

County Jails Struggle With A New Role As America’s Prime Centers For Opioid Detox

In Massachusetts last July, several Franklin County Jail inmates were watched by a nurse and a corrections officer after receiving their daily doses of buprenorphine, a drug that helps control opioid cravings. By some estimates, at least half to two-thirds of today’s U.S. jail population has a substance use or dependence problem.

Elise Amendola/AP


hide caption

toggle caption

Elise Amendola/AP

Faced with a flood of addicted inmates and challenged by lawsuits, America’s county jails are struggling to adjust to an opioid health crisis that has turned many of the jails into their area’s largest drug treatment centers.

In an effort to get a handle on the problem, more jails are adding some form of medication-assisted treatment, or MAT, to help inmates safely detox from opioids and stay clean behind bars and after release.

But there are deep concerns about potential abuse of the treatment drugs, as well as worries about the efficacy and costs of programs that jails just weren’t designed or built for.

“It was never traditionally the function of jail to be a treatment provider, nor to be the primary provider of detoxification in the country — which is what they have become,” says Andrew Klein, the senior criminal justice research scientist with the company Advocates for Human Potential, which advises on jail and prison substance abuse treatment programs across the U.S. “So, with the opioid epidemic, jails are scrambling to catch up.”

A “critical situation”

The National Sheriffs’ Association estimates that at least half to two-thirds of today’s jail population has a drug abuse or dependence problem. Some counties say the number is even higher.

“We are in a critical situation,” says Peter Koutoujian, a leading voice on the issue and the sheriff of Middlesex County, Mass. — one of the states hardest hit by the opioid epidemic.

“We have to physically, medically detox about 40% of our population as they come in off the street,” he says, “and probably 80 to 90% of our population inside has some type of drug or alcohol dependence.”

Koutoujian, who is also vice president of the Major County Sheriffs of America, says how best to treat opioid-addicted inmates is among the most pressing issues facing jails today.

“We have not been able to get our hands around it because, quite honestly, society has not gotten its hand around either preventing [drug-addicted] people from coming into our institutions or supporting them once they get back outside,” he says.

“The fact is you shouldn’t have to come to jail to get good [treatment] programming,” says Koutoujian. “You should be able to get that in your own community so you don’t have to have your life disrupted by becoming incarcerated.”

An ever-growing number of jails — 85 percent of which are run by local sheriffs — are trying to expand the use of medication-assisted addiction treatment behind bars, including the use of buprenorphine and methadone, among other drugs.

“Dead addicts don’t recover”

Jails in states hardest hit by opioids — including Ohio, Kentucky, West Virginia, Rhode Island and Massachusetts — are moving fastest to expand this use of medicine, which is now widely considered the most effective method of treating opioid use disorder. The National Sheriffs’ Association recently put out a detailed best practices guide to jail-based medication-assisted treatment, in conjunction with the National Commission on Correctional Health Care.

“Dead addicts don’t recover. So this is our opportunity to engage this population,” says Carlos Morales the director of correctional health services for California’s San Mateo County, just south of San Francisco.

Morales is working to expand access to medications for an older model of drug treatment that has long relied on abstinence and a “cold turkey” approach.

“We know if you are an opiate user you come in here, you detox, and you go out — it’s a 40 percent chance of OD-ing,” Morales says. “And we have the potential to do something about it.”

Felipe Chavez, who’s doing time at the San Mateo jail for selling fentanyl, is taking part in the jail’s fledgling opioid treatment program. Chavez says opioids have ruled his life since he started using oxycodone pills at age 12, following an injury.

“I was smoking them,” Chavez says. “Then I went to heroin. Then heroin went to fentanyl.”

With his sleepy eyes and loose-fitting clothes, Chavez looks younger than his 23 years – a little like a teenager in baggy pajamas. But the bright hunter-orange of everything he’s wearing, down to the plastic Crocs, all signify he’s in the San Mateo County jail’s infirmary in Redwood City, Calif., where he gets his regular dose of methadone.

Still, Chavez is one of the lucky ones here. Because he was in a local methadone program before he got arrested — again — he has been allowed to keep using that synthetic opioid substitute in jail. Methadone and a couple other drugs help jailed opioid users like Chavez temper cravings and, in theory, stay off more powerful and destructive opioids.

“It’s all about if you want to get clean or not, you know,” Chavez says. “The methadone is just there to help, you know. I mean, you’ve got to dedicate to the methadone. Because you got to start somewhere.”

With the methadone treatment he says, “I just feel more normal — like a normal person.”

Jail as an “opportunity to intervene”

Doctors who treat people in jails say a challenge — and an opportunity — in expanding the use of methadone or another medical treatment is that it’s not clear, at first at least, how big a role opioid addiction is playing in an inmate’s troubles; their drug use is often intertwined with mental health problems.

“The opiate part of the problem is usually not part of the charging documents, so it’s hard to tell,” says Dr. Robert Spencer, San Mateo County’s correctional health medical director. Addiction, mental health and crime “are so intimately connected,” Spencer says. “It’s often a form of self-medication, an attempt by them to modify their symptoms. This gives us an opportunity to provide an intervention and a possible way forward.”

More research is needed to confirm the long-term benefits of treating addiction in jail, addiction specialists say. But, so far, studies have shown that medication-assisted treatment works well in reducing fatal overdoses, relapse and in reducing the spread of infectious diseases, such as HIV.

Still, this kind of medication-based approach is relatively new in San Mateo — as it is for many jails across the country. For nearly a quarter century, San Mateo’s flagship addiction treatment program has been an abstinence-based approach called Choices. So far, only a dozen or so of the jails’ roughly 1,000 inmates are undergoing some sort of medication-assisted treatment.

Correctional health director Morales wants to expand those numbers. But he has lingering worries about costs, effectiveness and safety. He says inmates can hoard — and then sell, trade or abuse — some of the opioid treatment drugs, which are among the most top contraband items in jails today.

In addition, prison reforms in California to reduce overcrowding and reclassify some sentences has resulted in county jails housing more inmates for longer periods.

That, Morales says, has increased a kind of recidivist merry-go-round: a growing number of inmates with multiple bookings and short jail stays; people who aren’t getting the treatment they often need.

“I don’t think our script is good yet,” he says. “We don’t explain it well [to inmates], and we have to get better at advocating that someone use medicated-assisted treatment — and to get the protocol right, so that it’s not isolated folks that are doing it.”

Jails need to build the momentum of routine treatment by getting staff and inmates who have been helped talking about the success of this approach, he says. “And frankly, we’re not scaled up enough. Those are the challenges that we’re facing.”

It’s a similar story nationally, where the number of jails offering medication for inmates who are addicted is small.

Only 10% to 12% of the nation’s 4,000 jails are trying some form of addiction medication as part of treatment.

“Although this number is not the majority of jails, five years ago it was zero,” says Klein. “And the number is increasing every week.”

Some are offering access to the opioid substitute drugs buprenorphine and methadone, which can help opioid users detox and then temper cravings. Long term, in theory, those drugs can help people who have become addicted to opioids stay off of destructive and potentially deadly street versions.

But the majority of jail-based medication-assisted treatment programs today are limited to injectable naltrexone, given upon an inmate’s release.

Also known by its brand name Vivitrol, naltrexone is an injectable drug that could trigger withdrawal symptoms in someone who is physically dependent on opioids; but it also blocks the brain’s receptors for opioids and alcohol for 28 days.

Inmates who have been addicted to opioids are at far greater risk for overdose upon release, as their tolerance for street drugs is often greatly reduced after a stint of abstinence. Suddenly, a dose that got them high in the old days could now be fatal.

Liability concerns and the need to improve withdrawal management are also driving the increase in medication-assisted treatment. About 80%

. of all detoxification for drugs and alcohol happen in jails and prisons. And nationally, in the last 10 years, counties and states have paid out well over $70 million for addiction withdrawal-related deaths of inmates, according to a tally by Klein. More than 50 similar lawsuits are still pending.

Klein says the challenge is far broader than jails for a public health system that has yet to catch up to the opioid crisis. “MAT is totally underutilized in the community, much less in jails,” he says.

The problem is particularly hard for jails in more rural and semi-rural counties, which often have limited access to medications, to physicians who will administer it, and to follow-up programs that inmates can tap into upon release.

To provide methadone, for example, a jail has to either be certified as a methadone clinic or partner with a community clinic.

“Even if [rural jails] wanted to provide medication-assisted treatment within the jails, there may not be a methadone clinic for 60 miles,” says Carrie Hill, director of the National Sheriffs’ Association’s center for jail operations. “It’s a huge issue.”

Or a county may not have a doctor with the necessary licenses to provide treatment medications, Hill says.

Most rural areas “don’t have a single doctor who is certified to even prescribe buprenorphine,” says Klein. “So it’s very difficult for a jail to even find a doctor who can prescribe it to an inmate who may need it. Most rural and suburban counties in this country don’t have any methadone clinics they can rely on.”

Hill says the sheriffs in her group are working on ways to expand treatment and recovery support services to rural areas, including city-rural treatment partnerships; additional funding to greatly expand telemedicine and broadband services; and mobile anti-opioid addiction units that could deliver treatment drugs to hard-to-reach jails.

The group is in conversation with its federal partners to get the necessary medical waivers to do that.

Advocates for expanding MAT say the medications are saving lives. “In jail, [when] we have somebody stabilized — off street drugs — they can begin to calm down and [we can] find out if we can help them with medication,” Klein says. “What a tragedy if we miss that moment.”

The legislature in Massachusetts, with Koutoujian’s encouragement, has given the green light for a seven-county pilot program of the best evidence-based opioid treatment in jails. Starting this August, the jails will offer all forms of medication-assisted treatment and carefully track data on efficacy — including rates of drug relapse, overdose and recidivism.

While he supports MAT in general, Koutoujian, the sheriff, says he’s wary that medications alone will solve the inmate addiction treatment problem. That kind of thinking, he says, got us into this crisis in the first place.

“Medication-assisted treatment is very important but people have to remember if you do the medication without the treatment portion — the counseling and the supports — it will fail. And we will just fall prey to another easy solution that just simply does not work.”

“We have to make sure, if we are going to use medication-assisted treatment,” Koutoujian says, “that when they leave our facility they will have access to medication. Do they have health insurance to cover that medication? Do they have access to counseling and treatment services and navigators to help them through this most difficult time period? If they don’t have that, then in many ways we could be setting them up for greater failure.”

Meanwhile, in San Mateo’s jail, inmate Felipe Chavez says he wants to serve his time, reconnect with an infant daughter he barely knows and try “to live a different life.”

“I mean, I know everyone says that while they’re in here,” Chavez says. “But, you know, I’m really trying to just get my family back together. Change the way of life.”

To do that, Chavez says, for now he wants to stay in the jail’s fledgling medication-assisted treatment program — to help him stay off fentanyl and stay alive.

Let’s block ads! (Why?)


No Image

Drug Distributor And Former Execs Face First Criminal Charges In Opioid Crisis

Former Rochester Drug Co-Operative CEO Laurence Doud III, facing criminal charges stemming from the opioid crisis, leaves the federal courthouse in Manhattan on Tuesday.

Kathy Willens/AP


hide caption

toggle caption

Kathy Willens/AP

A major pharmaceutical distribution company and two of its former executives are facing criminal charges for their roles in advancing the nation’s opioid crisis and profiting from it.

Rochester Drug Co-Operative Inc., one of the nation’s 10 largest pharmaceutical distributors in the U.S., its former CEO Laurence Doud III and former chief of compliance William Pietruszewski were charged with conspiracy to distribute controlled narcotics — oxycodone and fentanyl — for non-medical reasons and conspiracy to defraud the United States.

RDC and Pietruszewski are also charged with willfully failing to file suspicious order reports to the Drug Enforcement Administration.

Between May 2012 and November 2016, the company received and filled over 1.5 million orders for controlled substances from its pharmacy customers. However, it reported only four suspicious orders to the DEA. According to the complaint, the company failed to report at least 2,000 suspicious orders.

“This prosecution is the first of its kind: executives of a pharmaceutical distributor and the distributor itself have been charged with drug trafficking, trafficking the same drugs that are fueling the opioid epidemic that is ravaging this country,” U.S. Attorney for the Southern District of New York Geoffrey Berman said in a statement. “Our Office will do everything in its power to combat this epidemic, from street-level dealers to the executives who illegally distribute drugs from their boardrooms.”

Geoffrey Berman, U.S. Attorney for the Southern District of New York, speaking at a news conference announcing charges against Rochester Drug Co-Operative Inc.

Mary Altaffer/AP


hide caption

toggle caption

Mary Altaffer/AP

Pietruszewski, 53, pleaded guilty last week. Doud, 75, surrendered to authorities and pleaded not guilty in federal court in Manhattan on Tuesday.

Both executives face maximum sentences of life in prison and a mandatory minimum prison term of 10 years on the drug trafficking charges. They face a maximum five years in prison on the charge of defrauding the government.

The Rochester, N.Y.,-based company is a middleman between drug manufacturers and local independent pharmacies. It supplied more than 1,300 pharmacies and earned $1 billion per year during the relevant time period.

According to the U.S. Attorney’s statement:

“From 2012 to 2016, RDC’s sales of oxycodone tablets grew from 4.7 million to 42.2 million — an increase of approximately 800 percent — and during the same period RDC’s fentanyl sales grew from approximately 63,000 dosages in 2012 to over 1.3 million in 2016 — an increase of approximately 2,000 percent. During that same time period, Doud’s compensation increased by over 125 percent, growing to over $1.5 million in 2016.”

The company has agreed to pay a $20 million fine and submitted to three years of independent compliance monitoring.

“Today’s charges should send shock waves throughout the pharmaceutical industry reminding them of their role as gatekeepers of prescription medication,” said DEA Special Agent in Charge Ray Donovan.

“We made mistakes,” company spokesman Jeff Eller said in a statement. “RDC understands that these mistakes, directed by former management, have serious consequences. We accept responsibility for those mistakes. We can do better, we are doing better, and we will do better.”

Let’s block ads! (Why?)


No Image

Rochester Drug Cooperative Faces Federal Criminal Charges Over Role In Opioid Epidemic

NPR’s Audie Cornish talks with Gary Craig, a Democrat and Chronicle reporter, about the first major pharmaceutical distributor to face federal criminal charges over its role in the opioid epidemic.



AUDIE CORNISH, HOST:

Today Rochester Drug Cooperative became the first pharmaceutical distributer to face federal criminal charges for its role in the opioid epidemic. RDC is charged with conspiring to distribute drugs and defrauding the federal government. The charges are a result of a two-year investigation that began after it was found that RDC ignored pill limits for pharmacies and catered to doctors who over-prescribe.

Gary Craig is an investigative reporter with the Democrat and Chronicle newspaper in Rochester, N.Y. Welcome to the program.

GARY CRAIG: Thanks for having me.

CORNISH: Give us some background on the lawsuit that led to the two-year investigation. What were the red flags for the Drug Enforcement Administration?

CRAIG: Well, it – you know, it appears the criminal and civil investigation began back in 2017. And you know, what they discovered according to court papers – and RDC has pretty much admitted to this – is that clear warning signs from the pharmacies that RDC distributes to – clear warning signs that they were just sort of excessively pushing out opioids were ignored by RDC or, even when highlighted internally by compliance officers, were not brought to the attention of DEA as required.

CORNISH: What does that mean? What kind of signals are we talking about?

CRAIG: There’s a number of them that the federal prosecutors mentioned, things like excessive purchases with cash in some pharmacies, purchases from well out of the region of the pharmacies. And these are opioid purchases we’re talking about – excessively high percentages of sales of fentanyl patches and opioid oxycodone painkillers from some pharmacies and some of the larger pharmacies that RDC dealt with. So those are some of the things that the feds highlighted.

CORNISH: Two RDC executives face charges. What are they accused of?

CRAIG: Basically sort of being players in this whole, you know, alleged kind of ignorance or willing ignorance, I should say, of RDC’s role in the opioid epidemic, the things we talked about – you know, just sort of closing your eyes to pharmacies that were obviously pushing painkilling prescription meds onto the streets in big numbers. And the allegations are that the former CEO, Larry Doud, and former compliance officer were key in allowing this to happen internally and just ignored all the signs. One has pleaded guilty and is cooperating. And Doud is facing the criminal charges.

CORNISH: You’ve talked a lot about the pharmacies here. And so I’m wondering, what about them? And what about the doctors making the orders? Are they being held accountable?

CRAIG: Well, it’s an interesting relationship. The Rochester Drug Cooperative, as the name obviously implies, is a cooperative. Its very members – sort of voting members, et cetera – are the 1,300 pharmacies to which it distributes medications. So the New York attorney general last month filed lawsuits against a number of pharmaceutical manufacturers and RDC as well, claiming that this sort of breeds almost an incestuous relationship where when your very members or the people who are your entity itself are the ones that are selling the pharmaceuticals, you have less of a willingness to basically do the right thing.

CORNISH: Is this a sign of things to come? I mean, is this setting an important precedent in terms of this being criminal charges?

CRAIG: I would think so. You know, as they clearly highlighted at the news conference today – the federal authorities in Manhattan – that this is the first of its kind. And obviously they’ve turned a corner with law enforcement as far as making this decision that instead of solely pursuing these things civilly, they’re going to now pursue criminally. So I would assume that we would see other federal prosecutions of a similar nature.

CORNISH: Gary Craig is an investigative reporter with the Democrat and Chronicle newspaper. Thanks so much.

CRAIG: Thank you.

Copyright © 2019 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.

Let’s block ads! (Why?)


No Image

The Traffic Tariff

Stacey congestion pricing

Darius Rafieyan

As cities all over the world grow, they’re struggling with crowded streets and polluted air. New York City has decided to try out one possible solution: congestion pricing. Drivers will soon be charged a toll to enter certain crowded neighborhoods. Officials hope it will cut down on traffic and bring in badly needed funds to help repair the city’s public transportation system.

Today on the show, Stacey Vanek Smith and Darius Rafieyan venture out into Midtown Manhattan during rush hour to see if congestion pricing is the solution that New York needs.

Music: “Jet Set Go”. Find us: Twitter / Facebook / Newsletter.

Subscribe to our show on Apple Podcasts, PocketCasts and NPR One.

Let’s block ads! (Why?)


No Image

Google Searches For Ways To Put Artificial Intelligence To Use In Health Care

Google is looking to artificial intelligence as a way to make a mark in health care.

Michael Short/Bloomberg via Getty Images


hide caption

toggle caption

Michael Short/Bloomberg via Getty Images

One of the biggest corporations on the planet is taking a serious interest in the intersection of artificial intelligence and health.

Google and its sister companies, parts of the holding company Alphabet, are making a huge investment in the field, with potentially big implications for everyone who interacts with Google — which is more than a billion of us.

The push into AI and health is a natural evolution for a company that has developed algorithms that reach deep into our lives through the Web.

“The fundamental underlying technologies of machine learning and artificial intelligence are applicable to all manner of tasks,” says Greg Corrado, a neuroscientist at Google. That’s true, he says, “whether those are tasks in your daily life, like getting directions or sorting through email, or the kinds of tasks that doctors, nurses, clinicians and patients face every day.”

Corrado knows a bit about that. He helped Google develop the algorithm that Gmail uses to suggest replies.

The company also knows the value of being in the health care sphere. “It’s pretty hard to ignore a market that represents about 20 percent of [U.S.] GDP,” says John Moore, an industry analyst at Chilmark Research. “So whether it’s Google or it’s Microsoft or it’s IBM or it’s Apple, everyone is taking a look at what they can do in the health care space.”

Google, which provides financial support to NPR, made a false start into this field a decade ago. The company backed off after a venture called Google Health failed to take root. But now, Google has rebooted its efforts.

Hundreds of employees are working on these health projects, often partnering with other companies and academics. Google doesn’t disclose the size of its investment, but Moore says it’s likely in the billions of dollars.

One of the prime movers is a sister company called Verily, which this year got a billion-dollar boost for its already considerable efforts. Among its projects is software that can diagnose a common cause of blindness called diabetic retinopathy and that is currently in use in India. Verily is also working on tools to monitor blood sugar in people with diabetes, as well as surgical robots that learn from each operation.

“In each of these cases, you can use new technologies and new tools to solve a problem that’s right in front of you,” says cardiologist Jessica Mega, Verily’s chief medical and scientific officer. “In the case of surgical robotics, this idea of learning from one surgery to another becomes really important, because we should be constantly getting better.”

Mega says the rise of artificial intelligence isn’t that big a departure from devices we’re used to, like pacemakers and implantable defibrillators, which jump into action in response to health signals from the body. “So patients are already seeing this intersection between technology and health care,” she says. “It’s just we’re hitting an inflection point.”

That’s because the same kinds of algorithms that are giving rise to self-driving cars can also operate in the health care sphere. It’s all about managing huge amounts of data.

Hospitals have gigabytes of information about the typical patient in the form of electronic health records, scans and sometimes digitized pathology slides. That’s fodder for algorithms to ingest and crunch. And Mega says there’s a potential to wring a lot more useful information out of it.

“There’s this idea that you are healthy until you become sick,” she says, “but there’s really a continuum” between health and disease. If computer algorithms can pick up early signs of a slide toward disease, that could help people avoid getting sick.

But medical data aren’t typically collected for research purposes, so there are gaps. To close those, Verily has partnered with Duke University and Stanford University in an effort called Project Baseline, which seeks to recruit 10,000 volunteers to give tons more data to the company.

Judith Washburn and her husband, James Davis, have volunteered to be subjects in Project Baseline, an effort to gather a range of detailed data to characterize and predict how people move from health to illness.

Courtesy of James Davis


hide caption

toggle caption

Courtesy of James Davis

Judith Washburn, a 73-year-old medical librarian and resident of Palo Alto, Calif., signed up after she saw a recruiting ad. “A couple months later, I got a call to go in, and it’s two days of testing, two different weeks and it’s very thorough,” she says.

She had heart scans, blood tests, skin swabs and stress tests — a checkup on steroids, if you pardon the expression. Her husband, James Davis, decided he’d give it a go as well.

“They were having trouble finding African-American participants at the time, so I was pretty much a shoo-in,” he says. “I’m aware of people who donate their bodies to medical science when they die,” he says, “so it’s sort of a way of donating your body while it’s still alive.”

The retired aerospace engineer also got an added benefit. The doctors diagnosed a serious heart condition, and Davis then had triple bypass surgery to treat it.

The couple replies to quarterly questionnaires, a gizmo under their mattress tracks their sleep patterns and they each wear a watch that monitors their hearts. The watches also count their steps — sort of.

“They haven’t quite figured out your exercise yet,” Washburn says. “In fact, I can knit and get steps!”

All this highly personal information goes into the database of a private corporation. Both Washburn and Davis thought about that before signing up but ultimately concluded that’s OK.

“It depends upon what they’re using it for,” Washburn says. “And if it’s all for research, I’m fine with that.”

Here’s what makes Google’s position unique. Some of the most useful data could be what the company collects while you’re running a Google search, using Gmail or using its Chrome browser.

“As companies like Google and other traditional consumer-oriented companies start moving into this space, it is certainly clear that they bring the capability of taking much of the information they have about us and be able to apply it,” says Reed Tuckson, a well-known academic physician who was recently recruited to advise Verily about Project Baseline.

For example, people’s browsing history can reveal a lot about what they buy, how they exercise and other facets of their lifestyles.

“We now understand that that has a great deal to do with the health decisions that we make,” says Tuckson, who is on a National Academy of Medicine working group that’s exploring artificial intelligence in medicine.

He says Google needs to tread carefully around these privacy issues, but he’s bullish on the technology.

“We should remember that the status quo is not acceptable by itself and that we’ve got to use every tool at our disposal — use them intelligently” to improve the health of Americans, he says. “And I think that’s why it’s exciting.”

Tuckson isn’t the only influential recruit to the effort. Verily recently brought in Dr. Robert Califf, a former Food and Drug Administration commissioner, as well as Vivian Lee, a radiologist who headed the University of Utah’s health care system. Google hired David Feinberg, a physician who ran Geisinger, a major health care provider based in Danville, Pa.

“It seems like it was a bit of a war on talent right now between Amazon and Google and to a certain extent Apple,” says Moore, the analyst. Google needs to build credibility in the medical sphere.

“I think Google is trying to have those people that can basically proof out what Google is doing and stand up and say, ‘Yes, Google can do this,’ ” Moore says.

He also has his eye on what the company’s investment means for the rapidly developing industry around health care and artificial intelligence. “Anyone should take Google very seriously,” he says.

Some big players, like Apple and Microsoft, can hold their own.

“For other AI companies that don’t have those resources, they’re going to have to be very judicious in picking the niches they want to target, niches that are ones that, frankly, Google is not terribly interested in,” Moore says.

Getting the technology to work is just the start.

The health care business is “a very complex ecosystem,” says Dr. Lonny Reisman, a former health insurance executive who now heads HealthReveal, a company that develops algorithms to help doctors choose the appropriate therapy. Google will need to answer many questions as it enters that landscape.

Who will have an incentive to buy software based on artificial intelligence? Will it really save time or money, as advocates often assert? Or is it just the next new driver of health care inflation?

“There are all these competing forces around cost containment,” Reisman says. It’s not easy to balance innovation, access, fairness and health equity, he adds, “so they’ve got a lot on their plate.”

Google’s Corrado says collaborations with academics and the health care industry are key for navigating this territory.

“A big part of the way that research and development should work in this space is by having kind of a long-term portfolio of technologies that you percolate through the academic and scientific community and then you percolate through the clinical community,” Corrado says.

For all the challenges of forging a new path into health care, Google has a potentially enormous advantage in all the data it collects from its billions of users.

Corrado says the company is well aware of the sensitivity of putting that information to use and is thinking about how to approach that without provoking a backlash.

“It has to be something that is driven by the patients’ desire to use their own information to better their wellness,” Corrado says.

In a world where people are increasingly concerned about how their personal data are exploited, that could be even more of a challenge than building the computer algorithms to digest and interpret it all.

You can contact NPR science correspondent Richard Harris at rharris@npr.org.

Let’s block ads! (Why?)


No Image

Kate Smith’s ‘God Bless America’ Dropped By Two Major Sports Teams

Singer Kate Smith signs autographs for a group of American sailors circa 1938.

Hulton Archive/Getty Images


hide caption

toggle caption

Hulton Archive/Getty Images

The singer Kate Smith’s recording of “God Bless America” has been a cherished part of sports tradition in the U.S. for decades. But in the aftermath of a discovery that the singer also recorded at least two songs with racist content in the 1930s, two major American sports teams, baseball’s New York Yankees and ice hockey’s Philadelphia Flyers, have announced that they will stop playing Smith’s rendition of the Irving Berlin patriotic classic. On Sunday, the Flyers also took down a statue of Smith that had stood in front of their stadium since 1987.

A fan alerted the Yankees last week that Smith had recorded at least two problematic songs — 1931’s “That’s Why Darkies Were Born” and 1933’s “Pickaninny Heaven,” from the film Hello, Everybody! — the New York Daily News reported on Thursday.

On Sunday, the Philadelphia Flyers removed a statue of Smith that had stood outside the team’s arena since 1987, first at the Spectrum and later at the Xfinity Live! venue. Smith sang “God Bless America” live for the Flyers before Game 6 of the 1974 Stanley Cup finals — after which the Flyers beat the Boston Bruins. Since then, the Flyers had treated Smith’s rendition as a talisman for the team.

YouTube

In a statement published Sunday, Flyers President Paul Holmgren said, “The NHL principle ‘Hockey is for Everyone’ is at the heart of everything the Flyers stand for. As a result, we cannot stand idle while material from another era gets in the way of who we are today.”

The statement also said: “While Kate Smith’s performance of ‘God Bless America’ cannot be erased from its place in Flyers history, that rendition will no longer be featured in our game presentations.”

On Friday, the Philadelphia team had covered the statue with black cloth. A spokesman for the Flyers told NBC10 in Philadelphia on Friday, “We have recently become aware that several songs performed by Kate Smith contain offensive lyrics that do not reflect our values as an organization.” The spokesman added, “As we continue to look into this serious matter, we are removing Kate Smith’s recording of ‘God Bless America’ from our library and covering up the statue that stands outside of our arena.”

Smith’s career spanned more than five decades and encompassed radio, multiple television shows under her name, commercials and over two dozen albums and hundreds of singles. But it seems that no official working for either team was aware of these two songs.

The Yankees had played Smith’s recording of “God Bless America” during the seventh-inning stretch since shortly after the Sept. 11 terrorist attacks. A spokesperson told the Daily News last Thursday, “The Yankees have been made aware of a recording that had been previously unknown to us and decided to immediately and carefully review this new information. The Yankees take social, racial and cultural insensitivities very seriously. And while no final conclusions have been made, we are erring on the side of sensitivity.”

Smith, who died in 1986 at age 79, received the Presidential Medal of Freedom — the United States’ highest civilian honor — from President Ronald Reagan in 1982 in honor of her artistic and patriotic contributions. In his remarks, Reagan said: “It’s been truly said that one of the most inspiring things our GIs in World War II, Europe and the Pacific, and later in Korea and Vietnam, ever heard was the voice of Kate Smith — and the same is true for all of us. … Those simple but deeply moving words, ‘God bless America,’ have taken on added meaning for all of us because of the way Kate Smith sang them. Thanks to her, they have become a cherished part of all our lives, an undying reminder of the beauty, the courage and the heart of this great land of ours.”

YouTube

Smith was a foundational figure in pop culture during World War II and used her fame to raise hundreds of millions of dollars for the U.S. government’s war efforts. During one 18-hour broadcast on the CBS radio network alone, she helped raise more than $100 million in war bonds. (That would amount to more than $1.4 billion in 2019 dollars.)

YouTube

In the 1933 film, Smith said that she was singing “Pickaninny Heaven” for “a lot of little colored children, who are listening in at an orphanage in New York City.” The sequence includes shots of unkempt black children, while Smith sings of a “pickaninny heaven” where “Mammy” is waiting for them as well as “great big watermelons.”

YouTube

“That’s Why Darkies Were Born” was written for a 1931 Broadway revue called “George White’s Scandals,” a show that featured such stars of the time as Rudy Vallee and Ethel Barrymore.

Some critics have argued that the “Darkies” song was meant to be a satire of white supremacist ideas — and it was famous enough in its day to be referenced in the Marx Brothers film Duck Soup. But modern-day audiences inevitably cringe at lines like “Someone had to pick the cotton / Someone had to plant the corn / Someone had to slave and be able to sing / That’s why darkies were born.”

“That’s Why Darkies Were Born” was also recorded by the pioneering and revered black bass baritone Paul Robeson — who, in his contract for EMI between 1928 and 1939, recorded quite a few songs that many contemporary listeners will find very problematic, including “De Li’l Pickaninny’s Gone to Sleep,” Stephen Foster’s plantation songs and “Poor Old Joe” (aka “Old Black Joe”).

Let’s block ads! (Why?)


No Image

Not Just Child’s Play: World Tiddlywinks Champions Look To Reclaim Their Glory

A tiddlywinks game mid-play, with winks spread out around the pot. Though players eventually want to “pot” their “winks,” players also strategize how to block their opponents by landing their piece on top of another’s piece.

Claire Harbage/NPR


hide caption

toggle caption

Claire Harbage/NPR

In 1995, Sports Illustrated likened Larry Kahn and David Lockwood to the Muhammad Ali and Joe Frazier of Tiddlywinks. A fearsome metaphor for two men who, in the parlance of their game, spend their time squopping and potting, rather than bobbing and weaving.

Kahn has won 114 national and world Tiddlywinks titles. Lockwood has won 41. “Larry is the Ali,” Lockwood concedes.

But their rivalry is a friendly one, and when they’re not competing against one another, they make a formidable pair. As a duo, they’ve won five international titles together.

On Friday, they’ll look to snap a 21-year drought when they try for their sixth title together at the annual Tiddlywinks World Championships at the University of Cambridge.

Larry Kahn (left) and Dave Lockwood, practice tiddlywinks. The game has a startlingly simple premise for a game that draws an academic fandom.

Claire Harbage/NPR


hide caption

toggle caption

Claire Harbage/NPR

On a recent afternoon in a simply remodeled basement located in the Virginia suburbs, Lockwood paces the perimeter of a regulation 6-by-3-foot table in gym socks and red track pants, calculating his best move.

Colorful, dime-sized discs, or winks, dot the felt-matted surface. In the center lies a traditional plastic red cup no bigger than a shot glass. Kahn, wearing Tevas over his socks, is playing in shorts, as usual, lest he gets too warm circling the tabletop.

tktk

Credit: Claire Harbage/NPR

Tiddlywinks has a startlingly simple premise: Shoot the most winks into the cup. For all its academic fandom, the very name of the game and its companion slang evokes the lexicon of a nursery rhyme. But Lockwood is quick to blast the game’s reputation as a bygone children’s pastime.

“Tiddlywinks is not what you did when you were 5 years old,” he says. “Tournament tiddlywinks is a fascinating combination of physical skill at a micro level and positional strategy.”

Larry Kahn (left) and Dave Lockwood are both friends and competitors.

Claire Harbage/NPR


hide caption

toggle caption

Claire Harbage/NPR

What began as a 19th century adult parlor game in England, first patented in 1888, reemerged in university circles across the United Kingdom and the United States as a tournament game held at Cambridge University in 1955.

Over time, professional winkers, largely recruited from Cambridge, Oxford and the Massachusetts Institute of Technology, helped heighten its complexity and strategy.

Probability, physics and dexterity rule the game.

Offensively, potting — or sinking a wink in the cup — depends on how much pressure a player exerts on the squidger, a larger disc used to flick smaller discs, or winks, into the cup. To gauge your potting chances, competitors know that pressure equals distance, Lockwood explains.

Trophies collected from tiddlywinks competitions over the years.

Claire Harbage/NPR


hide caption

toggle caption

Claire Harbage/NPR

To keep opponents from scoring, players use their winks for another purpose: squopping. Translation: they flick their winks on top of their opponent’s discs to effectively take them out of play.

“You need to defend the ones that you’ve got and/or attack the ones that they’ve got,” Lockwood explains.

These days, there’s hardly a market for the niche sport. Several companies don’t even make the equipment anymore.

So committed winkers have had to get creative. Lockwood and Kahn have procured orthopedic felt for their playing surface. They make their own squidgers by sanding down plastic discs molded from spice jar lids. They’re banking on 3-D printing becoming more affordable in the near future to help streamline the process.

It’s not something they could have imagined when they started playing Tiddlywinks during their freshman year at MIT, when Kahn and Lockwood each signed themselves up on a whim. Kahn thought the game sounded fun to learn. Lockwood checked “Tiddlywinks” as a joke, he says, after perusing the list of activities offered in the student handbook.

“I was the last person to make the eight-player team in 1972,” he says.

Dave Lockwood plays tiddlywinks.

tktk

Credit: Claire Harbage/NPR

Larry Kahn has won 114 national and world titles.

tktk

Credit: Claire Harbage/NPR

Today, Lockwood says the game has changed his life. “I’ve been to Britain more than 100 times since then, mostly to play Tiddlywinks.”

It’s a sentiment shared by Kahn, who says the game has “enriched my life.”

Kahn and Lockwood both say that one of the best parts of belonging to the winking community has been the friendships they’ve gained.

“Immediately you have a bond with people I’ve never met and it’s continued on, through today. For whatever reason, the game has sort of kept people together to some extent.”

Kahn crafts his own squidgers from pieces of plastic.

Claire Harbage/NPR


hide caption

toggle caption

Claire Harbage/NPR

Of course, when talk turns to this week’s tournament, they turn less sentimental.

“It’d be nice to you know, as old as we are compared to the other players, be able to to go in and win a match,” Kahn says. “To show the old guys can still do it.”

Lockwood is blunter. “I really want this,” he says. For him, the victories are addicting.

“If you get a modicum of success, you’re more frequently willing to continue to play, but it’s also a very frustrating game because you miss these things that you’ve made so many times in the past,” he says.

“But only the past is certain.”

Let’s block ads! (Why?)


No Image

WalletHub CEO: Growing Credit Card Debt Is An Economic Warning Sign

NPR’s Lulu Garcia-Navarro speaks with Odysseas Papadimitriou, CEO of WalletHub, about growing credit card debt and what it means for the economy.



LULU GARCIA-NAVARRO, HOST:

The U.S. economy is going strong with record low unemployment, but that’s not the whole story. Many Americans got smaller tax refunds this year. Wage growth is stagnant. And credit card debt is on the rise.

ODYSSEAS PAPADIMITRIOU: There is a significant group of our society that is kind of left behind.

GARCIA-NAVARRO: That’s Odysseas Papadimitriou, CEO of the personal finance website WalletHub. We’ve heard about credit card debt being a problem for middle and working classes before, but it’s now become an issue for the upper-middle class. Papadimitriou says they’re in the sweet spot for this type of easy lending.

PAPADIMITRIOU: It is the consumer group that wants to take on some additional debt and also has the income and the assets to justify so.

GARCIA-NAVARRO: On top of that, recent numbers show that people approaching retirement age are also accruing larger amounts of credit card debt.

PAPADIMITRIOU: You know, they’re away from retirement enough years to feel like, I will make up for it later on. Let me go and make this purchase. And then they end up later on in retirement with credit card debt.

GARCIA-NAVARRO: Credit card debt is at its highest level since 2008. WalletHub is projecting that each U.S. household will have an average of $9,300 in credit card debt by the end of the year. And Papadimitriou believes it’s hitting a breaking point.

PAPADIMITRIOU: We start defaulting. Credit card companies stop lending. More people get into trouble. Interest rates go up. Penalty fees go up. And you get into a vicious cycle…

GARCIA-NAVARRO: That could have larger repercussions.

PAPADIMITRIOU: …Which is, obviously, negative for the economy as well with spending power going down.

GARCIA-NAVARRO: The level of credit card debt is one economic warning sign. But Papadimitriou worries that lawmakers and consumers aren’t taking it seriously. He says it could take the threat of a recession to get them to act.

PAPADIMITRIOU: We’ll be going into a recession the next couple of years. I think the question is, when? If that recession comes before the election, I think, absolutely, it’s going to be a major political headwind, if you will. If it comes afterwards, it’s going to benefit, I think, the current administration.

GARCIA-NAVARRO: His advice – just because you have credit available to you doesn’t mean you should use it.

(SOUNDBITE OF MUSIC)

Copyright © 2019 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.

Let’s block ads! (Why?)